Table 3.
Health-Related Quality of Life According to the Results of Interferon-Based Antiviral Therapy in Korean Patients with Chronic HCV Infection
| Antiviral treatment naïve (n=98) | On treatment (n=49) | Sustained virologic responders (n=36) | Treatment failure or intolerance (n=52) | p-value | |
|---|---|---|---|---|---|
| SF-36 domain score | |||||
| PF | 73.8±24.4 | 81.4±19.7 | 81.5±23.7 | 74.0±20.9 | 0.109 |
| RP | 67.2±32.8 | 67.2±32.0 | 87.2±22.9* | 75.1±27.3 | 0.005 |
| BP | 71.7±27.0 | 69.0±27.1† | 77.9±26.6 | 72.6±26.7 | 0.503 |
| GH | 50.2±21.9 | 58.5±18.9 | 59.8±17.1 | 50.5±25.0 | 0.030 |
| VT | 47.2±23.5 | 48.5±24.5 | 60.4±23.3† | 50.4±24.7 | 0.041 |
| SF | 77.4±26.1 | 79.3±24.8 | 90.6±18.3 | 78.8±23.7 | 0.045 |
| RE | 74.8±31.6 | 73.0±32.3 | 86.6±27.1 | 78.5±27.9 | 0.167 |
| MH | 62.6±24.6 | 64.5±22.7 | 70.7±23.7 | 66.3±21.9 | 0.341 |
| SF-36 summary score | |||||
| PCS | 47.7±8.9 | 49.5±7.5 | 51.6±7.1 | 48.2±8.3 | 0.084 |
| MCS | 45.0±11.8 | 44.9±12.7 | 50.2±10.5 | 46.7±10.9 | 0.110 |
| EQ-5D profile (11111) | 34 (34.7) | 18 (36.7) | 15 (41.7) | 15 (28.9) | 0.651 |
| EQ-5D VAS | 65.8±18.4 | 68.5±16.9 | 68.1±16.1 | 72.8±19.0 | 0.242 |
| EQ-5D index | 0.834±0.138 | 0.870±0.121 | 0.875±0.156 | 0.835±0.166 | 0.277 |
Data are presented as mean±SD or number (%).
HCV, chronic hepatitis C virus; SF-36, Short Form 36; PF, physical functioning; RP, physical role functioning; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, emotional role; MH, mental health; PCS, physical component summary; MCS, mental component summary; EQ-5D, European quality of life questionnaire-5 dimensions; VAS, visual analogue scale.
p-value <0.05 compared with the treatment naïve group and the on-treatment group using Scheffe post hoc analysis;
p-value <0.05 compared with the treatment naïve group using Scheffe post hoc analysis.